SAN DIEGO, Calif., May 21, 2019 – Biotheranostics, Inc., today announced that Lee Newcomer, M.D., has been elected to its Board of Directors. Dr. Newcomer brings more than 30 years of healthcare experience including serving as the Chief Medical Officer of UnitedHealthcare and Senior Vice President Oncology and Genetics at UnitedHealthcare. He was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans and a former chairman of Park Nicollet Health Systems. He practiced medical oncology for nine years before joining the healthcare industry. Throughout his career, he has focused on making cancer care more effective and affordable. His expertise in medical oncology, medical care delivery, health plan strategy and management, payment systems and business development will contribute to Biotheranostics’ growth.

“We are pleased that Lee has accepted our invitation to join the Biotheranostics Board,” said Don Hardison, President and Chief Executive Officer. “His extensive experience in cancer care management and commercial health plans will be invaluable as we continue to rapidly grow our business and evolve our proprietary tests to address key unmet needs of the hundreds of thousands of patients diagnosed annually with early-stage breast cancer and metastatic cancer.”

Newcomer added, “I am excited to work with Biotheranostics as the company continues its important mission developing and providing accurate, actionable, molecular-based information for oncologists in order to better define the best individual treatment for cancer patients.”

About Biotheranostics

Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California. Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients. Its suite of proprietary molecular diagnostic tests provides important information to physicians to tailor treatment to individual patients. The company's Breast Cancer Index® and CancerTYPE ID® tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Learn more at biotheranostics.com.

 

Breast Cancer Index Intended Use and Limitations

BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.

Biotheranostics Page

Biotheranostics, Inc. | 9640 Towne Centre Drive | Suite 200 | San Diego, CA 92121 | Biotheranostics.com

US and International: +1 (858) 587-5870 | Fax: +1 (800) 266-9607 | Client Services: +1 (877) 886-6739 | Billing Information: +1 (888) 286-0755 | Patient Advocates Team: +1 (844) 319-8111

© 2018 Biotheranostics, Inc. Breast Cancer Index and BCI are service marks of Biotheranostics, Inc.

News and Press | Breast Cancer Index

 

SAN DIEGO, Calif., May 21, 2019 – Biotheranostics, Inc., today announced that Lee Newcomer, M.D., has been elected to its Board of Directors. Dr. Newcomer brings more than 30 years of healthcare experience including serving as the Chief Medical Officer of UnitedHealthcare and Senior Vice President Oncology and Genetics at UnitedHealthcare. He was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans and a former chairman of Park Nicollet Health Systems. He practiced medical oncology for nine years before joining the healthcare industry. Throughout his career, he has focused on making cancer care more effective and affordable. His expertise in medical oncology, medical care delivery, health plan strategy and management, payment systems and business development will contribute to Biotheranostics’ growth.

“We are pleased that Lee has accepted our invitation to join the Biotheranostics Board,” said Don Hardison, President and Chief Executive Officer. “His extensive experience in cancer care management and commercial health plans will be invaluable as we continue to rapidly grow our business and evolve our proprietary tests to address key unmet needs of the hundreds of thousands of patients diagnosed annually with early-stage breast cancer and metastatic cancer.”

Newcomer added, “I am excited to work with Biotheranostics as the company continues its important mission developing and providing accurate, actionable, molecular-based information for oncologists in order to better define the best individual treatment for cancer patients.”

About Biotheranostics

Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California. Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients. Its suite of proprietary molecular diagnostic tests provides important information to physicians to tailor treatment to individual patients. The company's Breast Cancer Index® and CancerTYPE ID® tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Learn more at biotheranostics.com.

 

Breast Cancer Index Intended Use and Limitations

BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.

Biotheranostics Page

Biotheranostics, Inc. | 9640 Towne Centre Drive | Suite 200 | San Diego, CA 92121 | Biotheranostics.com

US and International: +1 (858) 587-5870 | Fax: +1 (800) 266-9607 | Client Services: +1 (877) 886-6739 | Billing Information: +1 (888) 286-0755 | Patient Advocates Team: +1 (844) 319-8111

© 2018 Biotheranostics, Inc. Breast Cancer Index and BCI are service marks of Biotheranostics, Inc.